Time filter

Source Type

Kagoshima-shi, Japan

Kadooka M.,Perinatal Medical Center | Kato H.,Nanpuh Hospital | Kato A.,Perinatal Center | Ibara S.,Perinatal Medical Center | And 2 more authors.
Early Human Development | Year: 2014

Background: Fetomaternal hemorrhage (FMH) can cause severe morbidity. However, perinatal risk factors for long-term poor outcome due to FMH have not been extensively studied. Aims: To determine which FMH infants are likely to have neurological sequelae. Study design: A single-center retrospective observational study. Perinatal factors, including demographic characteristics, Kleihauer-Betke test, blood gas analysis, and neonatal blood hemoglobin concentration ([Hb]), were analyzed in association with long-term outcomes. Subjects: All 18 neonates referred to a Neonatal Intensive Care Unit of Kagoshima City Hospital and diagnosed with FMH during a 15-year study period. All had a neonatal [Hb] <. 7.5. g/dL and 15 of 17 neonates tested had Kleihauer-Betke test result >. 4.0%. Outcome measures: Poor long-term outcome was defined as any of the following determined at 12. month old or more: cerebral palsy, mental retardation, attention deficit/hyperactivity disorder, and epilepsy. Results: Nine of the 18 neonates exhibited poor outcomes. Among demographic characteristics and blood variables compared between two groups with poor and favorable outcomes, significant differences were observed in [Hb] (3.6. ±. 1.4 vs. 5.4. ±. 1.1. g/dL, P=. 0.01), pH (7.09. ±. 0.11 vs. 7.25. ±. 0.13, P=. 0.02) and base deficits (17.5. ±. 5.4 vs. 10.4. ±. 6.0. mmol/L, P=. 0.02) in neonatal blood, and a number of infants with [Hb]. ≤. 4.5. g/dL (78%[7/9] vs. 22%[2/9], P=. 0.03), respectively. The base deficit in neonatal arterial blood increased significantly with decreasing neonatal [Hb]. Conclusions: Severe anemia causing severe base deficit is associated with neurological sequelae in FMH infants. © 2014 Elsevier Ltd.

Tabata S.,Keio University | Ikeda R.,Kagoshima University | Yamamoto M.,Kagoshima University | Shimaoka S.,Nanpuh Hospital | And 6 more authors.
Oncotarget | Year: 2014

Thymidine phosphorylase (TP) promotes angiogenesis and metastasis, and confers resistance to anticancer agents in some cancer cell types. We previously reported that TP stimulates the expression of interleukin (IL)-8 in human KB cancer cells by an unknown mechanism. A mutation in the nuclear factor (NF)κB binding site of the IL-8 promoter suppressed promoter activity in KB/TP cells that overexpress TP. Specifically inhibiting NFκB by using BY11-7082 also suppressed TP-induced IL-8 promoter activity and IL-8 expression. Moreover, TP overexpression led to the activation of NFκB and an upregulation in the expression of its target genes, and increased phosphorylated IKKa/β protein levels, while promoting IκBa degradation as well as p65 phosphorylation and nuclear localization. The activation of NFκB in KB/TP cells was suppressed by the antioxidants N-acetylcysteine and EUK-8. In addition, in gastric cancer tissue samples, the expression of the NFκB-regulated genes, including IL-8, IL-6, and fibronectin-1 was positively correlated with TP expression. These findings indicate that reactive oxygen species mediated NFκB activation by TP increases the expression of genes that promote angiogenesis and metastasis in gastric cancer.

Jinguji M.,Nanpuh Hospital
Clinical Nuclear Medicine | Year: 2016

ABSTRACT: A 62-year-old man underwent a whole-body FDG PET/CT for annual cancer screening. By an interview, he had an epigastric pain, and his body temperature was 37.0°C on the day. He just came back home from a travel to Southeast Asia 1 week ago and had presented with chill, high fever (temperature, 39.6°C), arthralgia, myalgia, and skin rash a few days before. Dengue fever was diagnosed by detecting dengue virus type 1 genome and antibody to the virus accompanied by thrombocytopenia and leukopenia. PET/CT examination revealed increased FDG uptake in the spleen and multiple lymph nodes. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.

Yoshinaga T.,Kagoshima University | Shigemitsu T.,Kagoshima University | Nishimata H.,Nanpuh Hospital | Takei T.,Kagoshima University | Yoshida M.,Kagoshima University
Molecular Medicine Reports | Year: 2015

Globally, gastric cancer is one of the most common types of cancer and is the second leading cause of cancer-induced mortality. Early detection of gastric cancer is able to contribute to a reduction of its mortality. For early detection, more specific and sensitive biomarkers than the classic biomarkers, including carcinoembryonic antigen, carbohydrate antigen 19-9 and C-reactive protein, are required. The present study focused on the evaluation of the potential of angiopoietin-like protein 2 (ANGPTL2) as a novel biomarker for gastric cancer. The expression levels of ANGPTL2 in undifferentiated and differentiated gastric cancer cell lines (HGC-27 and MKN7, respectively) were therefore investigated. Additionally, ANGPTL2 levels in the serum of gastric cancer patients were compared with those of healthy individuals to evaluate the possibility of the protein as a predictive biomarker for gastric cancer. It was established that the expression levels of ANGPTL2 mRNA and protein were higher in undifferentiated HGC-27 cells than those in differentiated MKN7 cells. In a patient study, it was indicated that the levels of ANGPTL2 in the serum of gastric cancer patients were higher than those in healthy controls. The diagnostic performance of ANGPTL2 was assessed by constructing a receiver operating characteristic (ROC) curve and was evaluated by calculating the area under each ROC curve (AUC). For the discrimination of patients with gastric cancer from healthy individuals, the AUC for ANGPTL2 was 0.774 (P=0.005) (95% confidence interval, 0.615-0.933). These results suggested that ANGPTL2 was a potential biomarker for gastric cancer.

Sakaida I.,Yamaguchi University | Yamashita S.,Shimonoseki Kosei Hospital. | Kobayashi T.,Tohoku Rosai Hospital | Komatsu M.,Akita | And 4 more authors.
Journal of International Medical Research | Year: 2013

Objective: To investigate the efficacy and safety of 14 days' orally administered tolvaptan as adjunctive treatment for hepatic oedema in Japanese liver cirrhosis patients with insufficient response to conventional diuretics, with the option to increase dose in those who did not respond initially. Methods: This multicentre, single-arm, phase 3 study allocated patients with liver cirrhosis and persistent ascites to 7-day treatment with 7.5 mg/day tolvaptan followed by an additional 7 days' treatment. Responders at day 7 (achieving ≥1 kg body-weight reduction) continued on 7.5 mg/day tolvaptan; nonresponders (<1 kg body-weight reduction) received 15 mg/day tolvaptan. Conventional diuretic treatment continued throughout. The primary endpoint was change in body weight from baseline, as a marker of ascites volume. Results: A total of 51 patients received 7.5 mg/day tolvaptan for 7 days, which caused a significant reduction in mean body weight (55% response rate). During the second 7-day treatment period, 30 patients received 7.5 mg/day tolvaptan and 13 patients received tolvaptan 15 mg/day: response rates were 43% and 23%, respectively. Two serious adverse events were observed. Serum sodium was within normal range. © The Author(s) 2013.

Discover hidden collaborations